ClinicaliQ Trial Snapshot
- Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma — Recruiting • Non-phase study • Oncology • NCT05655078.
- Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).
- Sponsor: University College, London.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).
Eligibility Snapshot
- : * Patients ≥18 years of age, with biopsy confirmed MPM and histological subtyping (epithelioid or non-epithelioid) * N0 or N1 and M0 disease * Written informed consent * Patient and local/regional MDT opt for active surveillance and deferral of SACT until clinical or radiological progression * WHO Performance Status 0-1 * Disease confined to one hemithorax based on CT assessment * Adequate pulmonary function * ≥ 40% predicted post-FEV1; * ≥ 40% predicted DLCO/TLCO * Agreement to travel to either proton beam therapy centres (i.e. UCLH or The Christie) if randomised to arm 2 * Agreement to be followed up at a local HIT-Meso trial site * Patient likely able to complete PBT planning based on local assessment
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.